BCMA-CAR-natural killer (NK) cells and methods related thereto
AssigneeCaribou Biosciences, Inc.
InventorsLijun Wu, Vita Golubovskaya
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Claims16
A CAR-natural killer (NK) cell, comprising an anti-BCMA chimeric antigen receptor (CAR), comprising:
- an anti-BCMA single-chain variable fragment (scFv) comprising
- a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 3, and
- a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO:
- 5;
- a transmembrane domain;
- a co-stimulatory domain;
- and
- an activating domain.
A method of killing BCMA-positive cancer cells comprising:
- contacting the BCMA-positive cancer cells with a CAR-natural killer (NK) cell comprising an anti-BCMA chimeric antigen receptor (CAR) comprising
- an anti-BCMA single-chain variable fragment (scFv) comprising
- a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 3, and
- a light chain variable region VL) comprising the amino acid sequence of SEQ ID NO:
- 5;
- a transmembrane domain;
- a co-stimulatory domain;
- and
- an activating domain.
A method of making an anti-BCMA CAR-Natural Killer (NK) cell, comprising:
- introducing into an NK cell a nucleic acid encoding an anti-BCMA chimeric antigen receptor (CAR) comprising
- an anti-BCMA single-chain variable fragment (scFv) comprising
- a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 3, and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 5;
- a transmembrane domain;
- a co-stimulatory domain;
- and
- an activating domain.
Dependencies are inferred from the claim text.